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A recent paper reports that circulating tumor cells (CTCs) from metastatic breast cancer patients exhibit
heterogeneous epithelial and mesenchymal phenotypes and that CTCs display higher frequencies of partial
or full-blown mesenchymal phenotype than carcinoma cells within primary tumors. Mesenchymal-like CTCs
are also elevated in patients who are refractory to therapy.Cancer cell dissemination is a hallmark of
tumor progression that can potentially
lead to the establishment of clinically
detectable metastases (Talmadge and Fi-
dler, 2010). Cancer cells released from
primary tumors intravasate through lymph
or blood vessels. Much effort has been
devoted to the detection and character-
ization of circulating tumor cells (CTCs)
in the blood, tumor cells residing in the
sentinel lymph nodes, or disseminated
tumor cells (DTCs) in the bone marrow
(Pantel et al., 2009). Most current studies
focus on CTCs because amuch less inva-
sive clinical procedure is required to
obtain them, which permits frequent
monitoring. In addition, different enrich-
ment methods have been successfully
developed for blood but not for bone
marrow samples. These methods are
currently based on antibodies (Pantel
et al., 2009), cell deformability (Tan et al.,
2009), or cell size (Zheng et al., 2007).
CTC phenotyping and its comparison
with resident primary tumor cancer cells
should help to enhance our under-
standing of the mechanism of escape.
Experimental models show evidence
for collective or individual cell migration
at the periphery of primary tumors (Thiery,
2009). Collective cell migration was
postulated to be involved in lymph node
metastasis; such a mechanism could
also account for the dissemination of
tumor cell clusters and the formation of
microemboli within the primary tumor
bed vessels or in vessels at distant sites.
Epithelial-mesenchymal (EM) transition
(EMT), a well-described mechanism
driving major morphogenetic events in
metazoans, was also postulated to be272 Cancer Cell 23, March 18, 2013 ª2013 Eresponsible for CTC formation (Thiery,
2002). A recent study by Yu et al. (2013)
reported a detailed phenotypic analysis
of CTCs from patients with metastatic
breast cancer, revealing that a significant
number of CTCs exhibited a partial or
a full-blown EMT phenotype, supportive
of an EMT-driven mechanism (Figure 1).
CTCs can be enriched by loading a
blood sample through a high-throughput
microfluidic herringbone-chip or HbCTC-
Chip (Stott et al., 2010). This chip com-
prises a herringbone-patterned surface
that increases the interactions of
CTCs with an antibody directed against
EpCAM, an epithelial marker. However,
this method has been limited by the use
of a single antibody directed against one
relatively specific epithelial marker; this
could prevent the capture of CTCs exhib-
iting mesenchymal characteristics. To
overcome this issue, the authors coated
the surface of the HbCTC-Chip with
epithelial and breast molecular subtype-
specific antibodies, comprising a cocktail
of EpCAM, EGFR, and HER2. The
captured CTCs were phenotyped using
the HbCTC-chip via a quantitative immu-
nofluorescence-based RNA-in situ
hybridization (ISH) technology. The chip
was hybridized with a mixture comprising
custom-designed RNA probes directed
against epithelial (E) markers (CDH1,
EpCAM, KRT5, KRT7, KRT8, KRT18,
and KRT19) and mesenchymal (M)
markers (FN1, CDH2, and SERPINE1).
The captured cells were then classified
into five categories: purely E, intermediate
(E >M, E =M, andM> E), or purely M. The
RNA-ISH detection allowed customized
probes to be used against multiple genes,lsevier Inc.enabling dual staining and the precise
spectral analysis of the EM states of the
CTCs. Using a threshold of five CTCs in
3 ml of blood, 17 of 41 breast cancers
patients were considered positive, sug-
gesting that this method may not detect
CTCs in all metastatic patients. All 17
patients showed evidence of phenotypic
changes in the CTCs. Interestingly, a large
fraction of the CTCs were either double
E/M- or M-positive, particularly among
the HER2-positive and triple negative
subtypes. Analysis of a breast cancer
tissue microarray revealed that all ductal
carcinoma in situ showed an E pheno-
type, as expected, whereas invasive
carcinomas often contained cells with
dual phenotype (3.3% in estrogen/
progesterone [ER/PR]-positive, 2.7% in
HER2-positive, and 12.1% in triple
negative [TN] tumors). These data are
consistent with a tissue microarray study
of 479 samples that found that TN breast
cancers were particularly enriched in
carcinoma cells expressing a number of
mesenchymalmarkers, but it also showed
sporadic expression of some of these
mesenchymal markers in ER/PR-positive
tumors (Sarrio´ et al., 2008). Most interest-
ingly, the longitudinal study of ten patients
showed that, after targeted therapy,
CTCs from responding patients were
fewer in numbers and had a more epithe-
lial phenotype. Conversely, CTCs from
refractory patients were more numerous
and retained or acquired anM phenotype.
CTCs with a pronounced M phenotype
were also found in clusters. The question
then arises as to how these cells should
have formed aggregates, as it would be
expected that cells with a mesenchymal
Figure 1. Hypothetical Schematic to Describe the Origin and Subsequent Fate of CTCs
Cells with different epithelial/mesenchymal (EM) phenotypes can exit the primary tumor. Epithelial (E) cells
exit either through an epithelial-to-mesenchymal transition (EMT) or by other mechanisms that allow
cells to be released as single cells or clusters. Microemboli can arise from EM phenotypes or from E cells.
Subsequent EM phenotypes can be acquired through binding to platelets. At secondary sites, solitary
cells or clusters may acquire dormancy before resuming growth through an MET (mesenchymal-to-
epithelial transition) process. The metastatic tumor may express a similar proportion of EM phenotypes
than the primary tumor.
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Previewsphenotype should remain solitary (Fig-
ure 1). CTCs in blood can form microem-
boli, the presence of which indicates
a worsened prognosis, but mechanisms
driving microembolism formation remain
unclear. Microemboli could result from
the detachment of a cohesive group of
cancer cells from the primary tumor, or
they may be engulfed by invading neo-
vessels. Microemboli could also form
from isolated CTCs that undergo prolifer-
ation in a confined environment within the
capillary bed. Several intercellular adhe-
sion molecules, including N-cadherin,
type II cadherins, or CAM-Ig family
members, could be involved in clusterformation, even in E-cadherin-negative
CTCs, thus promoting survival in the
blood flow. Platelets also interact with
CTCs and promote CTC aggregation to
ensure immune escape. The present
study provides evidence that CTC clus-
ters are associated with platelets, which
ensures cohesion and simultaneously
induces a partial EMT phenotype through
TGF-b secretion and documents the EMT
phenotype by single-molecule RNA
sequencing. An elegant study performed
by Labelle et al. (2011) showed that
platelet-secreted TGF-b and the direct
interaction between platelets and cancer
cells can induce an EMT phenotypeCancer Cell 2through Smad and NF-kB pathways,
respectively.
The study by Yu et al. (2013) prompts
further investigations to better define the
EMT spectrum of CTCs and ascertain
their clinical relevance. Not all CTCs and
DTCs have a prognostic value (Pantel
et al., 2009). It will, therefore, be critical
to assess their clonogenic potential in
secondary sites and determine if the
EMT intermediate phenotype is, in fact,
most appropriate for the subsequent
clonal expansion of CTCs following
extravasation due to their ability to reac-
quire an epithelial-like phenotype (Thiery,
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